首页> 外文期刊>Biochemical Genetics >The polymorphism of DNA repair gene ERCC2/XPD Arg156Arg and susceptibility to breast cancer in a Chinese population.
【24h】

The polymorphism of DNA repair gene ERCC2/XPD Arg156Arg and susceptibility to breast cancer in a Chinese population.

机译:DNA修复基因ERCC2 / XPD Arg156Arg的多态性与中国人群对乳腺癌的易感性。

获取原文
获取原文并翻译 | 示例
           

摘要

Polymorphisms in DNA repair genes are good candidates for modifying cancer risk. ERCC2/XPD, a gene involved in nucleotide excision repair and basal transcription, may influence individual DNA repair capacity, particularly of bulky adducts. This is implicated in cancer susceptibility. To detect the association between ERCC2/XPD Arg156Arg and susceptibility to breast cancer in a Chinese population, we conducted a hospital-based case-control study consisting of 129 patients with breast cancer and 205 controls matched by age, gender, and ethnicity. PCR-RFLP was used for genotyping. No associations were found between ERCC2/XPD Arg156Arg and risk of breast cancer (AA/AC versus CC: OR = 0.79, 95% CI = 0.49-1.28, P = 0.33; AA versus CC: OR = 0.89, 95% CI = 0.49-1.63, P = 0.72; AC versus CC: OR = 0.74, 95% CI = 0.44-1.24, P = 0.25). Breast cancer cases with the variant AA genotype were marginally younger (mean age 45 years) than cases with the wild CC genotype (mean age 50 years) (P = 0.05). There were no differences in risk estimates in relation to menopause and occurrence of breast cancer. Our findings do not suggest that ERCC2/XPD Arg156Arg contributes to breast cancer susceptibility in a Chinese population.
机译:DNA修复基因中的多态性是改变癌症风险的良好候选者。 ERCC2 / XPD是一种涉及核苷酸切除修复和基础转录的基因,可能会影响单个DNA的修复能力,特别是大分子加合物的修复能力。这与癌症易感性有关。为了检测中国人群中ERCC2 / XPD Arg156Arg与乳腺癌易感性之间的关系,我们进行了一项基于医院的病例对照研究,该研究由129名乳腺癌患者和205名年龄,性别和种族相匹配的对照组成。 PCR-RFLP用于基因分型。在ERCC2 / XPD Arg156Arg与乳腺癌风险之间未发现关联(AA / AC与CC:OR = 0.79,95%CI = 0.49-1.28,P = 0.33; AA与CC:OR = 0.89,95%CI = 0.49 -1.63,P = 0.72; AC对CC:OR = 0.74,95%CI = 0.44-1.24,P = 0.25)。具有AA基因型变异的乳腺癌病例(平均年龄45岁)比具有野生CC基因型的乳腺癌病例(平均年龄50岁)略微年轻(P = 0.05)。与绝经和乳腺癌的发生有关的风险估计没有差异。我们的发现并不表明ERCC2 / XPD Arg156Arg有助于中国人群的乳腺癌易感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号